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INTRODUCTION
Inflammatory marker tests include 
C-reactive protein (CRP), plasma viscosity 
(PV), and erythrocyte sedimentation rate 
(ESR). Millions of inflammatory marker 
tests are done annually, and rates of testing 
are rising,1 with large variation in testing 
rates between different GP practices.2 
Measurement of inflammatory markers has 
two functions; it contributes to diagnosis 
of inflammatory conditions, including 
infections, autoimmune conditions, and 
cancers, and it is used to monitor disease 
progression or treatment response.3 
Inflammatory markers are recommended in 
a limited number of national guidelines, for 
example, as a first-line test for myeloma,4 
polymyalgia,5 and pneumonia.6 
A third use has crept into clinical practice; 
as a non-specific test to rule out serious 
underlying disease and provide patient and 
GP reassurance.7 Patients with non-specific 
symptoms, such as tiredness, memory 
problems, or gastrointestinal symptoms, may 
have inflammatory marker testing performed 
in order to exclude other diagnoses, as 
recommended in guidelines for chronic 
fatigue, dementia, and irritable bowel 
syndrome.8–10 There is a lack of evidence to 
back up this clinical practice. Unexpected 
results can be challenging to interpret, 
and false-positives may lead to increased 
uncertainty and anxiety for patients and 
GPs, and a cascade of further tests.11 False-
negatives may lead to false reassurance and 
delayed diagnosis of underlying diseases. 
The concept that abnormal test results 
can lead to cascade testing is not new,12,13 
yet little evidence of the frequency of 
cascade testing exists.14 Potential overuse 
of pathology tests is important given the 
current financial constraints within the NHS.
Much of the evidence about inflammatory 
markers comes from secondary care, and 
focuses on single disease outcomes.3 This 
is not helpful when testing is done for non-
specific symptoms, where multiple diseases 
are possible. The aim of this study was to 
identify the value of inflammatory marker 
testing in primary care as a rule-out test, 
provide evidence for GPs to interpret 
inflammatory markers, and to measure the 
cascade effects of testing in terms of follow-on 
blood tests, GP appointments, and referrals. 
METHOD
Participants and data sources
This was a prospective cohort study using 
the Clinical Practice Research Datalink 
(CPRD), which contains anonymised 
routinely collected data recorded from 
primary care electronic health records. 
Participants were 160 000 patients aged 
>18 years with an inflammatory marker 
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Abstract
Background
Inflammatory markers (C-reactive protein, 
erythrocyte sedimentation rate, and plasma 
viscosity) are commonly used in primary care. 
Though established for specific diagnostic 
purposes, there is uncertainty around their 
utility as a non-specific marker to rule out 
underlying disease in primary care.
Aim
To identify the value of inflammatory marker 
testing in primary care as a rule-out test, and 
measure the cascade effects of testing in terms 
of further blood tests, GP appointments, and 
referrals.
Design and setting
Cohort study of 160 000 patients with 
inflammatory marker testing in 2014, and 
40 000 untested age, sex, and practice-
matched controls, using UK primary care data 
from the Clinical Practice Research Datalink.
Method
The primary outcome was incidence of relevant 
disease, including infections, autoimmune 
conditions, and cancers, among those with 
raised versus normal inflammatory markers 
and untested controls. Process outcomes 
included rates of GP consultations, blood tests, 
and referrals in the 6 months after testing.
Results
The overall incidence of disease following a 
raised inflammatory marker was 15%: 6.3% 
infections, 5.6% autoimmune conditions, 3.7% 
cancers. Inflammatory markers had an overall 
sensitivity of <50% for the primary outcome, 
any relevant disease (defined as any infections, 
autoimmune conditions, or cancers). For 1000 
inflammatory marker tests performed, the 
authors would anticipate 236 false-positives, 
resulting in an additional 710 GP appointments, 
229 phlebotomy appointments, and 24 referrals 
in the following 6 months.
Conclusion
Inflammatory markers have poor sensitivity 
and should not be used as a rule-out test. 
False-positive results are common and lead to 
increased rates of follow-on GP consultations, 
tests, and referrals.
Keywords
diagnosis; inflammatory markers; primary care.
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taken in 2014. The inflammatory markers 
considered were CRP, ESR, and PV. The 
index date was defined as the first date of 
inflammatory marker testing in 2014. 
A comparison sample of 40 000 patients 
had no inflammatory marker test in 2014, 
though could have had testing at other 
dates. These were matched by age (in 5-year 
bands), sex, and practice to a random subset 
of 40 000 patients from the inflammatory 
marker test group. Controls were allocated 
the same index date as their matched case. 
Patients who had received a diagnosis of 
cancer, autoimmune conditions, or chronic 
infections in the 2 years before the index 
date were excluded, as were patients with 
an acute infection in the 30 days before the 
index date (Figure 1). 
Linked data included English Cancer 
Registry Data and patient level index of 
multiple deprivation (IMD). The authors 
did not solely study participants with data 
linkage in case this introduced bias. Cancer 
registry data were available for 110 245 
patients, IMD for 110 181.
Index tests
The authors defined a raised inflammatory 
marker using the mean upper limit of 
normal from laboratories within the study. 
For CRP, it was 6.8 mg/l, for simplicity 
rounded to 7 mg/l; for PV it was 1.72 mPa/s. 
For ESR, it was stratified by sex and age 
How this fits in
The utility of inflammatory markers as a 
general but non-specific test for possible 
serious underlying disease in primary 
care is poorly understood. In this large 
observational study using UK primary 
care electronic health records, the authors 
found that the most common cause of 
raised inflammatory marker is infection 
(6.3%), followed by autoimmune conditions 
(5.6%), and cancers (3.7%). Inflammatory 
markers have poor sensitivity, and should 
therefore not be used as a rule-out test. 
False-positive inflammatory marker 
results are common, and are associated 
with increased rates of follow-on GP 
consultations, tests, and referrals.
Identified by CPRD
n = 199 928
Age, sex, and
practice matching
Tested cohort
(>18 years, inflammatory
marker test in 2014)
n = 160 000
Cohort only
n = 120 000
Exclusions, N = 17 406 (14.5%):
• Results of index test missing n = 522
• Pre-existing cancer n = 2769
• Pre-existing autoimmune n = 7877
• Pre-existing infection n = 6237
• Spurious test result n = 1
Cohort only
n = 102 594
Subset for matching
n = 40 000
Exclusions, N = 5633 (14.1%):
• Results of index test missing n = 138
• Pre-existing cancer n = 923
• Pre-existing autoimmune n = 2550
• Pre-existing infection n = 2021
• Spurious test result n = 1
Matched tested
n = 34 367
Matched untested
n = 39 928a
Matched tested
n = 37 539
Untested cohort
n = 37 539
Total tested cohort, N = 136 961
CRP n = 97 203 (71.0%)
ESR n = 79 430 (58.0%)
PV n = 13 834 (10.1%)
Exclusions, N = 2389 (6.0%):
• Pre-existing cancer n = 797
• Pre-existing autoimmune n = 702
• Pre-existing infection n = 890
 
Figure 1. Flowchart showing exclusions. CPRD = 
clinical practice research datalink. CRP = C-reactive 
protein. ESR = erythrocyte sedimentation rate. 
PV = plasma viscosity. aMatched untested consists of 
39 928 subjects because, of the 40 000 from the cohort 
who were randomly selected for matching, 72 had no 
suitable age, sex, and practice-matched control.
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(further information is available from 
the authors on request). When the same 
inflammatory marker was repeated on the 
same day (n = 231), the authors retained 
the highest value. A binary variable for any 
raised inflammatory marker was generated 
to accommodate multiple testing.
Outcome variables
The primary outcome was any relevant 
disease, defined as cancer or autoimmune 
conditions coded within 1 year, or infection 
within 1 month of the index date. The 
authors considered infections beyond 
1 month unlikely to relate to the initial raised 
inflammatory marker. Process outcomes of 
repeat GP consultations, additional blood 
tests, and referrals were identified. For 
consultations, the authors included face-to-
face, home visit, and telephone consultations. 
Code list development
To identify cancers, the authors used 
validated code lists used in multiple 
previous studies (further details are 
available from the authors on request), 
as well as Cancer Registry Data. Clinical 
code lists for infections and autoimmune 
conditions were developed using validated 
methods,15 are broken down into subtypes 
(further information is available from the 
authors on request), and are available on 
the University of Bristol Data Repository.16
The authors searched the CPRD for 
symptom codes in the 28 days before 
and including the index date, retaining 
the 200 most frequently occurring codes, 
categorised according to the International 
Classification of Primary Care.17 They then 
used methods described previously15 to 
generate complete code lists for each of 
these symptoms. 
Sample size calculation
The CPRD were willing to offer a sample 
size of 160 000 tested patients. Power 
calculations with α = 0.05 and assuming 
that one-third of tests would be abnormal, 
with a baseline incidence of relevant disease 
of 7.5% (1% cancers, 1.5% autoimmune, 5% 
infections), gave 93% power to identify a 
change in incidence to 8%. For the least 
frequently occurring disease category, 
cancer, the authors had a 94% power to 
identify an increase from 1% to 1.2%. As the 
focus of the study was disease outcomes in 
tested patients, the untested group, used 
as a benchmark for the tested group, was 
deliberately kept small to ensure maximum 
power in the main study. 
Analysis
The primary analysis measured the overall 
incidence of relevant disease for patients 
with raised versus normal inflammatory 
markers, as well as tested versus untested 
patients, equivalent to the positive 
predictive value (PPV) in the test-positives. 
The authors used logistic regression for 
the dose–response relationship between 
CRP, ESR, and PV as continuous variables, 
and relevant disease as a binary variable, 
also generating a receiver-operating 
characteristic (ROC) curve. Summary 
statistics including sensitivity, specificity, 
PPV, and negative predictive value (NPV) 
were calculated for each of the three 
inflammatory markers. For ease of reading, 
the authors present many of the results 
for a primary care population of 1000. 
The reporting of this study conforms to 
the STARD18 and RECORD statements.19 
Analysis was performed using Stata 
(version 15).
 
RESULTS
Tests requested
After exclusions (Figure 1), the sample 
included 136 961 patients with one or more 
inflammatory marker test: 71.0% CRP, 
58.0% ESR, and 10.1% PV, plus 37 539 
untested. More than one inflammatory 
marker was performed simultaneously on 
the index date in 38.8%. Of the overall tested 
cohort, 27.8% had one or more raised 
inflammatory marker. 
Patient demographics 
Compared to the UK adult population, 
the tested cohort were more likely to be 
female (61.6% versus 51.3%), of white 
ethnicity (87.0% versus 85.4%), and from 
the most affluent socioeconomic quintile 
(23.0% versus 20%) (further information 
is available from the authors on request). 
Raised inflammatory markers were 
more common among the most deprived 
socioeconomic quintile (odds ratio [OR] 1.31, 
95% confidence interval [CI] = 1.24 to 1.38, 
P<0.001), and more common among 
females (OR 1.19, 95% CI = 1.16 to 1.22, 
P<0.001). There was no difference in the 
frequency of abnormal results by ethnicity. 
Incidence of disease 
The overall incidence of disease in patients 
with a raised inflammatory marker (PPV) was 
15.0% — 6.3% infections, 5.6% autoimmune 
conditions, and 3.7% cancers (Table 1). 
Of those with one or more raised 
inflammatory marker (n = 38 010), incidence 
of disease was highest among those with 
persistently raised inflammatory markers 
on subsequent testing, lower in those 
with normal inflammatory markers on 
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subsequent testing, and lowest among 
those without subsequent testing in the next 
90 days. Cancer was the notable exception; 
those with a normal subsequent test had a 
lower disease risk (2.1%) than those without 
repeat testing (3.6%). 
Figure 2 shows the incidence of disease 
according to test outcomes, simplified to a 
nominal population of 1000 tested patients. 
Of those with a positive test result, 85% 
had no evidence of infection, autoimmune 
condition, or cancer (false-positives). 
Table 2 summarises the detailed 
performance characteristics of each of 
the three tests (CRP, ESR, PV) for the 
primary outcome of any relevant disease, 
as well as for each of the three disease 
outcomes separately. All three tests had 
overall sensitivities of <50% for the primary 
outcome, any relevant disease (defined 
as infections, autoimmune conditions or 
cancers). 
Inflammatory marker levels
Incidence of disease increased with rising 
inflammatory marker levels in a dose–
Table 1. Disease incidence according to inflammatory marker test results
   Any relevant disease, Autoimmune  Infections, Cancer, 
   n (%) disease, n (%) n (%) n (%)
Untested (n = 37 539)  1293 (3.4) 200 (0.5) 760 (2.0) 354 (0.9)
Normal inflammatory markersa (n = 98 951)  5912 (6.0) 1652 (1.7) 2908 (2.9) 1503 (1.5)
Raised inflammatory markersb (n = 38 010)  5712 (15.0) 2121 (5.6) 2407 (6.3) 1407 (3.7)
Raised inflammatory markers,  No subsequent inflammatory 3471 (12.5) 1643 (5.9) 952 (3.4) 994 (3.6) 
subdivided according to markers done (n = 27 874)
subsequent test results Subsequent inflammatory 615 (18.6) 249 (7.5) 321 (9.7) 70 (2.1) 
(n = 38 010) markers normal (n = 3314)
  One or more raised inflammatory 1626 (23.8) 515 (7.6) 848 (12.4) 343 (5.0) 
  marker on subsequent testing  
  (n = 6822)
a All inflammatory marker tests normal. b One or more inflammatory markers raised.
Cohort Test result Actual diagnosis Implications
1000 people in
primary care with
inflammatory marker
tests done
Raised inflammatory
markers: 278 people
Normal inflammatory
markers: 722 people
Cancer: 10 people (3.7%)
Infections: 18 people (6.3%)
No relevant
disease: 236 people
(85.0%)
No relevant disease: 679
people (94.0%)
Cancer: 11 people
(1.5%)
Infections: 21
people (2.9%)
True positives: test may
help doctor reach correct
diagnosis (42 people)
False positives:
test may cause
anxiety and
cascade testing
(236 people)
True negatives: patient
and doctor appropriately
reassured (679 people)
False negatives:
patient and
doctor may be
falsely reassured
(43 people)
Autoimmune: 16 people
(5.6%)
Autoimmune: 12
people (1.7%)
Figure 2. Test implications flowchart. Numbers and 
percentages do not add up to 100% due to rounding 
and because a small number of people developed 
more than one relevant disease outcome.
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response relationship (Figures 3–5). With 
CRP ≥100 mg/L (n = 1552), 501 (32.3%) 
developed one or more relevant diseases: 
113 (7.2%) cancers, 99 (6.4%) autoimmune 
conditions, and 317 (20.4%) infections. 
With ESR ≥100 mm/h (n = 389), 141 
(36.3%) developed ≥one relevant diseases: 
59 (15.2%) cancers, 60 (15.4%) autoimmune 
conditions, and 36 (9.3%) infections. With 
PV ≥2 Pa/s (n = 276), 81 (29.3%) developed 
one or more relevant disease: 30 (10.9%) 
developed cancer, 38 (13.8%) developed 
autoimmune conditions, and 15 (5.4%) 
developed infections. 
Symptoms triggering testing
Table 3 shows the most common 
symptoms in the 28 days before testing, 
ordered according to the ratio between 
symptom frequency in test-positive versus 
test-negative groups. Broadly these could 
be categorised into non-specific symptoms, 
abdominal symptoms, joint symptoms, 
and infective symptoms. Non-specific 
symptoms such as tiredness, dizziness, and 
low mood were relatively more common in 
the test-negative compared to test-positive 
groups, indicating that these non-specific 
symptoms are less likely to generate raised 
inflammatory markers. In comparison, 
infective symptoms such as cough, UTI, 
and chest infection were more likely to 
be associated with a raised inflammatory 
marker. 
Diagnostic activity after initial 
inflammatory marker test
Table 4 shows the blood tests, appointments, 
and referrals in the 6 months after testing 
for true-positive, false-positive, true-
negative, or false-negative groups, plus 
untested controls. Follow-on blood tests, 
appointments, and referrals were higher in 
the false-positives than the true-negatives. 
Both groups consist of tested patients 
without subsequent pathology, with the main 
difference being the inflammatory marker 
result. Based on this, for 1000 inflammatory 
marker tests performed, the authors would 
expect 236 false-positives, associated with 
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Figure 3. Incidence of relevant disease in relation to 
test result for CRP. CRP = C-reactive protein.
Figure 4. Incidence of relevant disease in 
relation to test result for ESR. ESR = erythrocyte 
sedimentation rate.
Figure 5. Incidence of relevant disease in relation to 
test result for PV. PV = plasma viscosity.
For the small number (<0.5%) with one or more 
disease outcome; cancer superseded autoimmune 
disease, which superseded infections.
Table 3. Most frequently recorded symptoms in the 28 days before 
inflammatory marker testing 
  Normal Raised 
 Untested inflammatory inflammatory 
 (N = 37 539) markers (N = 98 951) markers (N = 38 010)
Symptom n % n % n %
Tiredness 82 0.22 6390 6.46 2148 5.65
Dizziness  126 0.34 2156 2.18 755 1.99
Headache 98 0.26 2498 2.52 965 2.54
Low mood 111 0.30 964 0.97 390 1.03
Low back pain 138 0.37 2079 2.10 857 2.25
Back pain 156 0.42 2202 2.23 964 2.54
Abdominal pain 166 0.44 7132 7.21 3232 8.50
Chest pain 100 0.27 1922 1.94 872 2.29
Rash 145 0.39 1663 1.68 797 2.10
Joint pain 52 0.14 2515 2.54 1215 3.20
Pain, generalised 87 0.23 1841 1.86 1011 2.66
Diarrhoea 64 0.17 2297 2.32 1266 3.33
Shoulder pain 123 0.33 1103 1.11 631 1.66
Throat symptoms 102 0.27 1018 1.03 598 1.57
Knee pain 182 0.48 1599 1.62 916 2.41
Nausea and vomiting 56 0.15 1171 1.18 720 1.89
Cough 496 1.32 3361 3.40 2336 6.15
Malaise 27 0.07 1005 1.02 720 1.89
UTI 189 0.50 1291 1.30 1057 2.78
Chest infection 130 0.35 720 0.73 804 2.12
Symptoms are ordered according to whether they were relatively more common in patients with normal 
inflammatory markers (top) or more common in those with raised inflammatory markers (bottom) 
UTI = urinary tract infection.
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an additional 710 GP appointments, 229 
phlebotomy appointments, and 24 referrals 
in the 6 months following testing. 
DISCUSSION
Summary
The authors examined the outcomes of 
inflammatory marker testing in UK primary 
care. Multiple simultaneous inflammatory 
markers were common, and abnormal 
results frequent. Testing was more common 
in females, in white ethnic groups, and in 
the most affluent. Conversely, abnormal 
results were more common in patients from 
the most socially-deprived socioeconomic 
groups. This is in keeping with the inverse 
care law,20 with potential overtesting in the 
affluent, and relative undertesting in more 
deprived groups. Higher testing rates may 
also in part reflect higher consultation rates 
in certain sociodemographic groups. 
Inflammatory markers have poor 
sensitivity, so are not suitable as a rule-out 
test. False-positive results were frequent, 
with increased rates of GP appointments, 
repeat blood tests, and referrals. In patients 
with a raised inflammatory marker, the 
most common diagnoses were infection 
(6.3%), followed by autoimmune conditions 
(5.6%), and cancers (3.7%). 
Strengths and limitations
The size of this study is a strength, along 
with the setting in primary care, where 
initial suspicion of disease usually arises. 
Examining multiple disease outcomes 
allowed the authors to explore the utility 
of testing to distinguish between healthy 
and unhealthy. This is relevant, as GPs 
describe using inflammatory markers in 
this way.7 The authors have also used a test 
consequences graphic, based on a nominal 
population of 1000 tested patients; this may 
help implementation into practice.21 
The main limitation is lack of information 
about the reason for testing. The authors 
cannot determine which tests were done 
for specific diagnostic purposes, and which 
were done as a general rule-out for any 
relevant underlying disease. The frequency 
of non-specific symptoms in the cohort 
(tiredness, malaise, dizziness, or low mood) 
suggests the latter is likely to be common. 
The benefit of this approach is that it reflects 
real life clinical practice; though GPs may 
not have a specific diagnosis in mind when 
they request inflammatory markers, they 
need to consider a wide range of possible 
diagnoses if the test is positive.
All studies using electronic health records 
rely on the quality of data recording. Blood 
tests are electronically transmitted to the 
GP records, reducing the risk of missing or 
erroneous data. The authors used rigorous 
methods to develop disease code lists,15 
but it is possible that there were some 
omissions. Furthermore, some diseases 
may be unrecorded, though this is rare for 
cancers and autoimmune disease.22 The 
authors omitted cardiovascular disease as 
an outcome; though CRP predicts future 
cardiovascular disease, it does not form part 
of any cardiovascular diagnostic algorithm. 
There is some risk of incorporation 
bias, particularly for infections, as these 
diagnoses may be more likely to be coded 
because of the inflammatory marker test 
result.
Table 4. Cascade effects of testing in 6-month period after testing
 Mean number of GP Mean number of Mean number of Mean number of 
 appointments per phlebotomy appointments total tests referrals per 
 persona (95% CI) in 6 months (95% CI) requested (95% CI) person (95% CI)
True-positives,  15.0b 4.26b 43.7b 0.86b 
n = 5712 (14.7 to 15.3) (4.15 to 4.37) (42.3 to 45.2) (0.83 to 0.89)
False-negatives,  12.0b 3.23b 30.0b 0.78b 
n = 5912 (11.7 to 12.2) (3.14 to 3.32) (28.8 to 31.2) (0.75 to 0.81)
False-positives,  10.3b 2.78b 24.3b 0.62b 
n = 32 298 (10.2 to 10.4) (2.75 to 2.82) (23.9 to 24.7) (0.61 to 0.64)
True-negatives,  7.29b 1.81b 13.7b 0.52b 
n = 93 039 (7.2 to 7.3) (1.80 to 1.83) (13.5 to 13.8) (0.51 to 0.52)
Untested controls  4.80 1.14 9.66 0.24 
n = 37 539 (4.74 to 4.86) (1.12 to 1.16) (9.47 to 9.85) (0.24 to 0.25)
True-positives = people with a positive test who develop relevant disease. False-negatives = people with a negative test who develop relevant disease. False-positives = people with 
a positive test with no relevant disease. True-negatives = people with a negative test with no relevant disease. aIncludes face-to-face consultations, home visits, and telephone 
consultations. bP<0.001 — comparing true-positives to false-negatives and comparing false-positives to true-negatives.
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Comparison with existing literature
Most previous studies of inflammatory 
markers consider single diseases, and most 
are based in secondary care. The current 
findings confirm the associations between 
inflammatory markers and infection and 
autoimmune conditions; however, the PPVs 
are lower in a primary care population with 
low prevalence for these conditions, and 
false-positives are more frequent.3
The cascade effects of medical technology 
have been described,12,23 yet there is limited 
evidence of the size of this effect.14 The 
authors identified a significant difference 
in the rate of GP consultations, blood tests, 
and referrals in the false-positive test result 
group. 
Current guidelines for chronic fatigue, 
irritable bowel disease, and suspected 
dementia recommend inflammatory 
marker testing in order to exclude other 
diagnoses.8–10 The current research is 
discordant with these guidelines, showing 
that, with an overall sensitivity of <50% 
inflammatory markers are not a useful test 
of exclusion. 
Implications for research and practice
Previous qualitative work has shown that 
doctors perceive inflammatory markers 
as a useful rule-out test.7 However, the 
sensitivity of inflammatory markers is poor, 
so they are not suitable for that purpose. 
Instead they are classic Bayesian tests, with 
a positive test somewhat increasing the 
chance of disease, though not definitively, 
and a negative test reducing the chance 
of disease, but not to zero. The authors 
therefore suggest that inflammatory 
marker tests should not be used as a 
non-specific test to rule out disease, or for 
patient reassurance. 
In patients with a raised inflammatory 
marker, the range of differential diagnoses is 
wide, explaining the additional consultations, 
tests, and referrals. With significantly raised 
inflammatory markers, the risk of disease is 
higher. In patients with unexplained raised 
inflammatory markers, risk of cancer must 
also be considered. Interpretation should 
take into account the reason for testing and 
the pre-test likelihood of disease; a negative 
test in the context of low-risk symptoms 
reduces disease likelihood further, but with 
the potential for harm from false-positive 
tests. False-negative tests may also lead to 
false reassurance, as patients with normal 
inflammatory markers are at significantly 
higher disease risk than untested controls. 
GPs should not be excessively reassured 
by a repeat negative inflammatory marker; 
the authors found higher disease incidence 
in those with normal repeat tests (18.6%) 
compared to those who did not have repeat 
tests performed (12.5%). Presumably this 
reflects the fact that the GP’s decision to 
repeat the test meant they were suspicious 
that the patient was ill. 
Though the unit cost of inflammatory 
marker tests is relatively low, the total 
costs, including follow-on consultations, 
investigations, and referrals, are likely to 
be substantial. As well as financial costs, 
patient anxiety and GP workload may 
be generated. Further studies including 
health economic evaluations may be 
useful to inform clinical guidelines and 
recommendations for GPs about when (and 
when not) to use inflammatory marker 
tests. They should also consider whether 
specific inflammatory markers are superior 
in certain diagnostic scenarios.
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